Molecular profiling of male breast cancer - Lost in translation?

International Journal of Biochemistry and Cell Biology

Volumn 53, Issue , 2014, Pages 526-535

  Johansson, Ida ^a   Killander, Fredrika ^a,b   Linderholm, Barbro ^c,d   Hedenfalk, Ingrid ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Intrinsic subtype; Male breast cancer; NAT1; Profiling; Prognosis

Indexed keywords

ESTROGEN RECEPTOR; MICRORNA; ARYLAMINE ACETYLTRANSFERASE; ISOENZYME; N-ACETYLTRANSFERASE 1;

BREAST CANCER; CANCER PROGNOSIS; CANCER SURVIVAL; COMPARATIVE STUDY; DATA BASE; DISEASE MARKER; EPIGENETICS; GENE EXPRESSION PROFILING; GENOMICS; HUMAN; IMMUNOHISTOCHEMISTRY; MALE BREAST CANCER; MOLECULAR TYPING; PREDICTIVE VALUE; REVIEW; BIOSYNTHESIS; BREAST TUMOR; CLASSIFICATION; FEMALE; GENETICS; MALE; MOLECULAR PATHOLOGY; PATHOLOGY; PROGNOSIS;

ARYLAMINE N-ACETYLTRANSFERASE; BREAST NEOPLASMS, MALE; FEMALE; HUMANS; ISOENZYMES; MALE; PATHOLOGY, MOLECULAR; PROGNOSIS;

EID: 84905033130     PISSN: 13572725     EISSN: 18785875     Source Type: Journal    
DOI: 10.1016/j.biocel.2014.05.007     Document Type: Review

References (113)

1. T.M. Abdel-Fatah, D.G. Powe, G. Ball, M.A. Lopez-Garcia, H.O. Habashy, and A.R. Green et al. Proposal for a modified grading system based on mitotic index and Bcl2 provides objective determination of clinical outcome for patients with breast cancer J. Pathol. 222 2010 388 399
2. T. Abdel-Fatah, G. Ball, A.K. Miles, P. Moseley, A. Green, and B. Rees et al. Identification of Sperm Associated Antigen 5 (SPAG5) as a novel biological and predictive biomarker in Breast cancer Cancer Res. 72 Suppl. 3 2012 10.1158/0008-5472.SABCS12-P6-07-26 Abstract number: P6-07-26
3. R. Agarwal, A.M. Gonzalez-Angulo, S. Myhre, M. Carey, J.S. Lee, and J. Overgaard et al. Integrative analysis of cyclin protein levels identifies cyclin B1 as a classifier and predictor of outcomes in breast cancer Clin. Cancer Res. 15 2009 3654 3662
4. W.F. Anderson, I. Jatoi, J. Tse, and P.S. Rosenberg Male breast cancer: a population-based comparison with female breast cancer J. Clin. Oncol. 28 2010 232 239
5. V.M. Basham, J.M. Lipscombe, J.M. Ward, S.A. Gayther, B.A. Ponder, and D.F. Easton et al. BRCA1 and BRCA2 mutations in a population-based study of male breast cancer Breast Cancer Res. 4 2001 R2
6. S.B. Baylin, and J.G. Herman DNA hypermethylation in tumorigenesis: epigenetics joins genetics Trends Genet. 16 2000 168 174 (Pubitemid 30169152)
7. I. Bièche, I. Girault, E. Urbain, S. Tozlu, and R. Lidereau Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma Breast Cancer Res. 6 2004 1 12
8. A. Blanco, M. Hoya, J. Balmaña, T. Ramón y Cajal, A. Teulé, and M.-D. Miramar et al. Detection of a large rearrangement in PALB2 in Spanish breast cancer families with male breast cancer Breast Cancer Res. Treat. 132 2011 307 315
9. F.M. Blows, K.E. Driver, M.K. Schmidt, A. Broeks, F.E. van Leeuwen, and J. Wesseling et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies PLoS Med 7 2010 e1000279
10. L.A. Brinton, D.A. Richesson, G.L. Gierach, J.V. Lacey, Y. Park, and A.R. Hollenbeck et al. Prospective evaluation of risk factors for male breast cancer J. Natl. Cancer Inst. 100 2008 1477 1481
11. L.A. Brinton, J.D. Carreon, G.L. Gierach, K.A. McGlynn, and G. Gridley Etiologic factors for male breast cancer in the U.S. Veterans Affairs medical care system database Breast Cancer Res. Treat. 119 2009 185 192
12. M. Callari, V. Cappelletti, L. Cecco, V. Musella, P. Miodini, and S. Veneroni et al. Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer Breast Cancer Res. Treat. 127 2010 601 610
13. Cancerfonden, S., 2013. Cancer i siffror 2013 1-64.
14. S. Centralbyrån Återstående medellivslängd för åren 1751-2012 2014 SCB
15. X. Chen, X. Liu, L. Zhang, S. Li, Y. Shi, and Z. Tong Poorer survival of male breast cancer compared with female breast cancer patients may be due to biological differences Jpn. J. Clin. Oncol. 43 2013 954 963
16. K. Chin, S. Devries, J. Fridlyand, P.T. Spellman, R. Roydasgupta, and W.-L. Kuo et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies Cancer Cell 10 2006 529 541 (Pubitemid 44854748)
17. G. Chodick, J.P. Struewing, E. Ron, J.L. Rutter, and J. Iscovich Similar prevalence of founder BRCA1 and BRCA2 mutations among Ashkenazi and non-Ashkenazi men with breast cancer: evidence from 261 cases in Israel, 1976-1999 Eur J Med Genet 51 2008 141 147 (Pubitemid 351374875)
18. F.J.F. Couch, L.M.L. Farid, M.L.M. DeShano, S.V.S. Tavtigian, K.K. Calzone, and L.L. Campeau et al. BRCA2 germline mutations in male breast cancer cases and breast cancer families Nat. Genet. 13 1996 123 125
19. B. Cutuli, C.C.-S. Le-Nir, D. Serin, Y. Kirova, Z. Gaci, and C. Lemanski et al. Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 cases Crit. Rev. Oncol. Hematol. 73 2010 246 254
20. S.-J. Dawson, O.M. Rueda, S. Aparicio, and C. Caldas Review: a new genome-driven integrated classification of breast cancer and its implications EMBO J. 32 2013 617 628
21. S. Deb, I. Johansson, D. Byrne, C. Nilsson, K. Investigators, and L. Constable et al. Nuclear HIF1A expression is strongly prognostic in sporadic but not familial male breast cancer 2014 Mod Pathol 10.1038/modpathol.2013.231 (Epub ahead of print)
22. S. Dedeurwaerder, C. Desmedt, E. Calonne, S.K. Singhal, B. Haibe-Kains, and M. Defrance et al. DNA methylation profiling reveals a predominant immune component in breast cancers EMBO Mol Med 3 2011 726 741
23. C. Desmedt, B. Haibe-Kains, P. Wirapati, M. Buyse, D. Larsimont, and G. Bontempi et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes Clin. Cancer Res. 14 2008 5158 5165
24. Y.C. Ding, L. Steele, C.-J. Kuan, S. Greilac, and S.L. Neuhausen Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States Breast Cancer Res. Treat. 126 2010 771 778
25. G. Engholm, J. Ferlay, N. Christensen, T.B. Johannesen, Å. Klint, and J.E. Køtlum et al. NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 5.3 (25.04.2013) 2013 Association of the Nordic Cancer Registries. Danish Cancer Society 1 2
26. P. Eroles, A. Bosch, J.A. Pérez-Fidalgo, and A. Lluch Molecular biology in breast cancer: intrinsic subtypes and signaling pathways Cancer Treat. Rev. 38 2012 698 707
27. M. Ewertz, L. Holmberg, S. Tretli, B.V. Pedersen, and A. Kristensen Risk factors for male breast cancer - a case-control study from Scandinavia Acta Oncol. 40 2001 467 471 (Pubitemid 32682030)
28. M. Falchetti, R. Lupi, P. Rizzolo, K. Ceccarelli, I. Zanna, and V. Calò et al. BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases Breast Cancer Res. Treat. 110 2007 161 167 (Pubitemid 351793854)
29. M. Fassan, R. Baffa, J.P. Palazzo, J. Lloyd, M. Crosariol, and C.-G. Liu et al. MicroRNA expression profiling of male breast cancer Breast Cancer Res. 11 2009 R58
30. I.S. Fentiman, A. Fourquet, and G.N. Hortobagyi Male breast cancer Lancet 367 2006 595 604 (Pubitemid 43247575)
31. L.S.L. Friedman, S.A.S. Gayther, T.T. Kurosaki, D.D. Gordon, B.B. Noble, and G.G. Casey et al. Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population Am. J. Hum. Genet. 60 1997 313 319
32. J. Fridlyand, A.M. Snijders, B. Ylstra, H. Li, A. Olshen, and R. Segraves et al. Breast tumor copy number aberration phenotypes and genomic instability BMC Cancer 6 2006 96
33. M. García-Closas, P. Hall, H. Nevanlinna, K. Pooley, J. Morrison, and D.A. Richesson et al. Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics PLoS Genet 4 2008 e1000054
34. Y. Ge, N. Sneige, M.A. Eltorky, Z. Wang, E. Lin, and Y. Gong et al. Immunohistochemical characterization of subtypes of male breast carcinoma Breast Cancer Res. 11 2009 R28
35. S.H. Giordano A review of the diagnosis and management of male breast cancer Oncologist 10 2005 471 479 (Pubitemid 41266328)
36. S.H. Giordano, M.A.U. Buzdar, and G.N. Hortobagyi Breast cancer in men Ann. Intern. Med. 137 2002 678 687 (Pubitemid 35176102)
37. S.H. Giordano, D.S. Cohen, A.U. Buzdar, G. Perkins, and G.N. Hortobagyi Breast carcinoma in men Cancer 101 2004 51 57
38. J.L. Gnerlich, A.D. Deshpande, D.B. Jeffe, S. Seelam, E. Kimbuende, and J.A. Margenthaler Poorer survival outcomes for male breast cancer compared with female breast cancer may be attributable to in-stage migration Breast Dis 23 2012 138 140
39. A. Goldhirsch, E.P. Winer, A.S. Coates, R.D. Gelber, M. Piccart-Gebhart, and B. Thürlimann et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer Ann. Oncol. 24 2013 2206 2223
40. J.M. Greif, C.M. Pezzi, V.S. Klimberg, L. Bailey, and M. Zuraek Gender differences in breast cancer: analysis of 13,000 breast cancers in men from the national cancer data base Ann. Surg. Oncol. 19 2012 3199 3204
41. J.I. Herschkowitz, K. Simin, V.J. Weigman, I. Mikaelian, J. Usary, and Z. Hu et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors Genome Biol. 8 2007 R76
42. K. Holm, C. Hegardt, J. Staaf, J. Vallon-Christersson, G. Jönsson, and H. Olsson et al. Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns Breast Cancer Res. 12 2010 R36
43. A.W. Hsing, J.K. McLaughlin, P. Cocco, H.T. Co Chien, and J.F. Fraumeni Risk factors for male breast cancer (United States) Cancer Causes Control 9 1998 269 275 (Pubitemid 28319019)
44. Z. Hu, C. Fan, D.S. Oh, J. Marron, X. He, and B.F. Qaqish et al. The molecular portraits of breast tumors are conserved across microarray platforms BMC Genomics 7 2006 96
45. R. Hultborn, C. Hanson, I. Köpf, I. Verbiené, E. Warnhammar, and A. Weimarck Prevalence of Klinefelter's syndrome in male breast cancer patients Anticancer Res. 17 1997 4293 4297 (Pubitemid 28081702)
46. I. Johansson, C. Nilsson, P. Berglund, C. Strand, G. Jönsson, and J. Staaf et al. High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancer Breast Cancer Res. Treat. 129 2011 747 760
47. I. Johansson, C. Nilsson, P. Berglund, M. Lauss, M. Ringner, and H. Olsson et al. Gene expression profiling of primary male breast cancers reveals two unique subgroups and identifies N-acetyltransferase-1 (NAT1) as a novel prognostic biomarker Breast Cancer Res. 14 2012 R31
48. I. Johansson, M. Ringner, and I. Hedenfalk The landscape of candidate driver genes differs between male and female breast cancer PLoS ONE 8 2013 e78299
49. P.A. Jones DNA methylation and cancer Oncogene 21 2002 5358 5360 (Pubitemid 34983472)
50. P.A. Jones, and S.B. Baylin The epigenomics of cancer Cell 128 2007 683 692 (Pubitemid 46273572)
51. G. Jönsson, J. Staaf, J. Vallon-Christersson, M. Ringner, K. Holm, and C. Hegardt et al. Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics Breast Cancer Res. 12 2010 R42
52. R. Kanthan, I. Fried, T. Rueckl, J.-L. Senger, and S. Kanthan Expression of cell cycle proteins in male breast carcinoma World J Surg Oncol 8 2010 10
53. M. Kaufmann, L. Pusztai, and Biedenkopf Expert Panel Members Use of standard markers and incorporation of molecular markers into breast cancer therapy: consensus recommendations from an International Expert Panel Cancer 117 2011 1575 1582
54. kConFab, A. Sauty de Chalon, Z. Teo, D.J. Park, F.A. Odefrey, and J.L. Hopper et al. Are PALB2 mutations associated with increased risk of male breast cancer? Breast Cancer Res. Treat. 121 2009 253 255
55. M. Klintman, C. Strand, C. Ahlin, S. Beglerbegovic, M.-L. Fjallskog, and D. Grabau et al. The prognostic value of mitotic activity index (MAI), phosphohistone H3 (PPH3), cyclin B1, cyclin A, and Ki67, alone and in combinations, in node-negative premenopausal breast cancer PLoS ONE 8 2013 e81902
56. D.C. Koboldt, R.S. Fulton, M.D. McLellan, H. Schmidt, J. Kalicki-Veizer, and J.F. McMichael et al. Comprehensive molecular portraits of human breast tumours Nature 490 2012 61 70
57. L.A. Korde, J.A. Zujewski, L. Kamin, S. Giordano, S. Domchek, and W.F. Anderson et al. Multidisciplinary meeting on male breast cancer: summary and research recommendations J. Clin. Oncol. 28 2010 2114 2122
58. R. Kornegoor, A.H.J. Verschuur-Maes, H. Buerger, M.C.H. Hogenes, P.C. de Bruin, and J.J. Oudejans et al. Molecular subtyping of male breast cancer by immunohistochemistry Mod. Pathol. 25 2011 1 7
59. R. Kornegoor, C.B. Moelans, A.H. Verschuur-Maes, M.C. Hogenes, P.C. de Bruin, and J.J. Oudejans et al. Promoter hypermethylation in male breastcancer: analysis by multiplex ligation-dependentprobe amplification Breast Cancer Res. 14 2012 R101
60. M.M. Lacle, C. van der Pol, A. Witkamp, E. van der Wall, and P.J. van Diest Prognostic value of mitotic index and bcl2 expression in male breast cancer PLoS ONE 8 2013 e60138
61. U. Lehmann, T. Streichert, B. Otto, C. Albat, B. Hasemeier, and H. Christgen et al. Identification of differentially expressed microRNAs in human male breast cancer BMC Cancer 10 2010 109
62. B.D. Lehmann, J.A. Bauer, X. Chen, M.E. Sanders, A.B. Chakravarthy, and Y. Shyr et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies J. Clin. Invest. 121 2011 2750 2767
63. E. Levy-Lahad, and E. Friedman Cancer risks among BRCA1 and BRCA2 mutation carriers Br. J. Cancer 96 2007 11 15 (Pubitemid 46094632)
64. A.A. Liede, B.Y.B. Karlan, and S.A.S. Narod Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature J. Clin. Oncol. 22 2004 735 742
65. D. Ly, D. Forman, J. Ferlay, L.A. Brinton, and M.B. Cook An international comparison of male and female breast cancer incidence rates Int. J. Cancer 132 2012 1918 1926
66. M. Medras, F. Alicja, J. Pawel, W. Jacek, and S.W. Teresa Breast cancer and long-term hormonal treatment of male hypogonadism Breast Cancer Res. Treat. 96 2006 263 265
67. Metabric Group The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups Nature 486 2012 346 352
68. H. Miao, H.M. Verkooijen, K.S. Chia, C. Bouchardy, E. Pukkala, and S. Laronningen et al. Incidence and outcome of male breast cancer: an international population-based study J. Clin. Oncol. 29 2011 4381 4386
69. R. Michalides, H. van Tinteren, A. Balkenende, J.B. Vermorken, J. Benraadt, and J. Huldij et al. Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment Br. J. Cancer 86 2002 402 408 (Pubitemid 34185125)
70. C. Nilsson, M. Holmqvist, L. Bergkvist, I. Hedenfalk, M. Lambe, and M.-L. Fjallskog Similarities and differences in the characteristics and primary treatment of breast cancer in men and women - a population based study (Sweden) Acta Oncol. 50 2011 1083 1088
71. C. Nilsson, I. Johansson, C. Ahlin, S. Thorstenson, R.-M. Amini, and M. Holmqvist et al. Molecular subtyping of male breast cancer using alternative definitions and its prognostic impact Acta Oncol. 52 2013 102 109
72. C. Nilsson, A. Koliadi, I. Johansson, C. Ahlin, S. Thorstenson, and L. Bergkvist et al. High proliferation is associated with inferior outcome in male breast cancer patients Mod. Pathol. 26 2013 87 94
73. E. Niméus-Malmström, A. Koliadi, C. Ahlin, M. Holmqvist, L. Holmberg, and R.-M. Amini et al. Cyclin B1 is a prognostic proliferation marker with a high reproducibility in a population-based lymph node negative breast cancer cohort Int. J. Cancer 127 2010 961 967
74. T. Ohayon, I. Gal, R.G. Baruch, C. Szabo, and E. Friedman CHEK2*1100delC and male breast cancer risk in Israel Int. J. Cancer 108 2004 479 480 (Pubitemid 37549616)
75. N. Orr, A. Lemnrau, R. Cooke, O. Fletcher, K. Tomczyk, and M. Jones et al. Genome-wide association study identifies a common variant in RAD51B associated with male breast cancer risk Nat. Genet. 44 2012 1182 1184
76. L. Ottini, P. Rizzolo, I. Zanna, M. Falchetti, G. Masala, and K. Ceccarelli et al. BRCA1/BRCA2 mutation status and clinical-pathologic features of 108 male breast cancer cases from Tuscany: a population-based study in central Italy Breast Cancer Res. Treat. 116 2008 577 586
77. J.S. Parker, M. Mullins, M.C.U. Cheang, S. Leung, D. Voduc, and T. Vickery et al. Supervised risk predictor of breast cancer based on intrinsic subtypes J. Clin. Oncol. 27 2009 1160 1167
78. C.M. Perou, T. Sørlie, M.B. Eisen, M. van de Rijn, S.S. Jeffrey, and C.A. Rees et al. Molecular portraits of human breast tumours Nature 406 2000 747 752
79. R. Pinto, B. Pilato, L. Ottini, R. Lambo, G. Simone, and A. Paradiso et al. Different methylation and microRNA expression pattern in male and female familial breast cancer J. Cell. Physiol. 228 2013 1264 1269
80. M.Y.C. Polley, S.C.Y. Leung, L.M. McShane, D. Gao, J.C. Hugh, and M.G. Mastropasqua et al. An International Ki67 Reproducibility Study J. Natl. Cancer Inst. 105 2013 1897 1906
81. A. Prat, J.S. Parker, O. Karginova, C. Fan, C. Livasy, and J.I. Herschkowitz et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer Breast Cancer Res. 12 2010 R68
82. A. Prat, M.C.U. Cheang, M. Martin, J.S. Parker, E. Carrasco, and R. Caballero et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal a breast cancer J. Clin. Oncol. 31 2013 203 209
83. D. Rayson, C. Erlichman, V.J. Suman, P.C. Roche, L.E. Wold, and J.N. Ingle et al. Molecular markers in male breast carcinoma Cancer 83 1998 1947 1955 (Pubitemid 28503726)
84. K.J. Ruddy, and E.P. Winer Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship Ann. Oncol. 24 2013 1434 1443
85. C. Rudlowski, H.-J. Schulten, M.M. Golas, B. Sander, R. Barwing, and J.-E. Palandt et al. Comparative genomic hybridization analysis on male breast cancer Int. J. Cancer 118 2006 2455 2460
86. H.G. Russnes, H.K.M. Vollan, O.C. Lingjaerde, A. Krasnitz, P. Lundin, and B. Naume et al. Genomic architecture characterizes tumor progression paths and fate in breast cancer patients Sci Transl Med 2 2010 38ra47
87. C.E. Scott-Conner, P.R. Jochimsen, H.R. Menck, and D.J. Winchester An analysis of male and female breast cancer treatment and survival among demographically identical pairs of patients Surgery 126 1999 775 780 [discussion 780-1]
88. A.M. Shaaban, G.R. Ball, R.A. Brannan, G. Cserni, A. Di Benedetto, and J. Dent et al. A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences Breast Cancer Res. Treat. 133 2012 949 958
89. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA: A Cancer J Clin 63 2013 11 30
90. V. Silvestri, P. Rizzolo, M. Falchetti, I. Zanna, G. Masala, and S. Bianchi et al. Mutation analysis of BRIP1 in male breast cancer cases: a population-based study in Central Italy Breast Cancer Res. Treat. 126 2010 539 543
91. V. Silvestri, P. Rizzolo, I. Zanna, M. Falchetti, G. Masala, and S. Bianchi et al. PALB2 mutations in male breast cancer: a population-based study in Central Italy Breast Cancer Res. Treat. 122 2010 299 301
92. V. Silvestri, P. Rizzolo, M. Falchetti, I. Zanna, G. Masala, and D. Palli et al. Mutation screening of RAD51C in male breast cancer patients Breast Cancer Res. 13 2011 404
93. Socialstyrelsen Cancer Incidence in Sweden 2011 2012 1 115
94. H.T.H. Sørensen, S.S. Friis, J.H.J. Olsen, A.M.A. Thulstrup, L.L. Mellemkjaer, and M.M. Linet et al. Risk of breast cancer in men with liver cirrhosis Am. J. Gastroenterol. 93 1998 231 233
95. T. Sørlie, C.M. Perou, R. Tibshirani, T. Aas, S. Geisler, and H. Johnsen et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc. Natl. Acad. Sci. U.S.A. 98 2001 10869 10874 (Pubitemid 32878711)
96. T. Sørlie, R. Tibshirani, J. Parker, T. Hastie, J.S. Marron, and A. Nobel et al. Repeated observation of breast tumor subtypes in independent gene expression data sets Proc. Natl. Acad. Sci. U.S.A. 100 2003 8418 8423 (Pubitemid 36842560)
97. V. Speirs, and A.M. Shaaban The rising incidence of male breast cancer Breast Cancer Res. Treat. 115 2008 429 430
98. A. Stang, and C. Thomssen Decline in breast cancer incidence in the United States: what about male breast cancer? Breast Cancer Res. Treat. 112 2008 595 596
99. J.P. Struewing, Z.M. Coriaty, E. Ron, A. Livoff, M. Konichezky, and P. Cohen et al. Founder BRCA1/2 mutations among male patients with breast cancer in Israel Am. J. Hum. Genet. 65 1999 1800 1802 (Pubitemid 30468698)
100. K. Syrjäkoski, T. Kuukasjärvi, A. Auvinen, and O.-P. Kallioniemi CHEK2 1100C is not a risk factor for male breast cancer population Int. J. Cancer 108 2003 475 476
101. Y.C. Tai, S. Domchek, G. Parmigiani, and S. Chen Breast cancer risk among male BRCA1 and BRCA2 mutation carriers J. Natl. Cancer Inst. 99 2007 1811 1814 (Pubitemid 351767200)
102. C. Thellenberg, B. Malmer, B. Tavelin, and H. Grönberg Second primary cancers in men with prostate cancer: an increased risk of male breast cancer J. Urol. 169 2003 1345 1348 (Pubitemid 36323781)
103. D.B.D. Thomas, L.M.L. Jimenez, A.A. McTiernan, K.K. Rosenblatt, H.H. Stalsberg, and A.A. Stemhagen et al. Breast cancer in men: risk factors with hormonal implications Am. J. Epidemiol. 135 1992 734 748
104. M. Tirkkonen, T. Kainu, N. Loman, O.T. Johannsson, H. Olsson, and R.B. Barkardottir et al. Somatic genetic alterations in BRCA2-associated and sporadic male breast cancer Genes. Chromosomes Cancer 24 1999 56 61 (Pubitemid 28544463)
105. S. Tommasi, A. Mangia, G. Iannelli, P. Chiarappa, E. Rossi, and L. Ottini et al. Gene copy number variation in male breast cancer by aCGH Anal Cell Pathol (Amst) 33 2010 113 119
106. J. Wang-Rodriguez, K. Cross, S. Gallagher, M. Djahanban, J.M. Armstrong, and N. Wiedner et al. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases Mod. Pathol. 15 2002 853 861 (Pubitemid 34919778)
107. M. Wasielewski, M.A. Bakker, A. Ouweland, M.E. Meijer-van Gelder, H. Portengen, and J.G.M. Klijn et al. CHEK2 1100C and male breast cancer in the Netherlands Breast Cancer Res. Treat. 116 2008 397 400
108. K. Weber-Chappuis, S. Bieri-Burger, and J. Hurlimann Comparison of prognostic markers detected by immunohistochemistry in male and female breast carcinomas Eur. J. Cancer 32A 1996 1686 1692 (Pubitemid 26306878)
109. B. Weigelt, F.C. Geyer, and J.S. Reis-Filho Histological types of breast cancer: how special are they? Mol Oncol 4 2010 192 208
110. J. White, O. Kearins, D. Dodwell, K. Horgan, A.M. Hanby, and V. Speirs Male breast carcinoma: increased awareness needed Breast Cancer Res. 13 2011 219
111. E. Yildirim, and U. Berberoǧlu Male breast cancer: a 22-year experience Eur. J. Surg. Oncol. 24 1998 548 552 (Pubitemid 28566902)
112. I.E. Young, K.M. Kurian, C. Annink, I.H. Kunkler, V.A. Anderson, and B.B. Cohen et al. A polymorphism in the CYP17 gene is associated with male breast cancer Br. J. Cancer 81 1999 141 143 (Pubitemid 29415504)
113. X.-F. Yu, W.-L. Feng, L.-L. Miao, B.-J. Chen, and H.-J. Yang The prognostic significance of molecular subtype for male breast cancer: a 10-year retrospective study Breast 22 2013 824 827